COREG CR will utilize Flamel's proprietary Micropump® technology, which controls the delivery of carvedilol helping to maintain appropriate amounts of medicine in the body over a 24-hour span. This technology allows COREG CR to be dosed once daily, in contrast to immediate-release COREG (carvedilol) tablets, which patients must take twice daily. GlaxoSmithKline plans to begin shipping COREG CR in the first quarter of 2007.This is an important drug for our patients with severe heart failure, based on the data from the COMET trial. The pricing is not yet available, but look for it to be a bit more than two standard Coreg tablets.
-Wes
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.